Condition: Breast Cancer · Sponsor: InventisBio Co., Ltd
This is a randomized, parallel-controlled, open-label, multicenter clinical study to assess the efficacy and safety of D-0502 in the treatment of subjects with ER-positive, HER2-negative locally advanced or metastatic breast cancer with fulvestrant injection as a control drug.
This description comes directly from the study's public registry record.
Yuting Li · 8615821378026 · yuting.li@inventisbio.com
Always discuss trial participation with your own doctor first.
| Cancer Hospital Chinese Academy of Medical Science | Beijing, Beijing Municipality, China | Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06954961